AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04094558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ingestible capsule
Description: Participants will swallow capsules and collect in stool concurrent with stool samples
Study NCT04094558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedated EGD
Description: Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.
Study NCT04094558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Hydrogen and methane breath test with lactulose substrate
Study NCT06000228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recession coverage with CTG using minimally invasive access technique in shallow vestibule
Description: After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
Study NCT06000228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recession coverage with CTG using minimally invasive access technique in deep vestibule
Description: After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
Study NCT06474338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: detection by artificial intelligence
Description: The bladder lesion(s) are detected by artificial intelligence algorithm.
Study NCT06474338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: detection by urologists
Description: The bladder lesion(s) are detected by urologists.
Study NCT04298047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participatory art-based activity
Description: The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
Study NCT05459363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-THINC
Description: Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
Study NCT06492122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]In-FL-020
Description: A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
Study NCT06492122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and urine samples collection
Description: For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020
Study NCT06492122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT/CT images
Description: For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.
Study NCT06599671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal niche resection
Description: In short: the bladder was carefully dissected away from the uterus towards the abdominal cavity to open the vesicovaginal space and reach the peritoneum. The fingers on the anterior wall isthmus could touch the obvious scar-like defect. The weak scar tissue then thoroughly was removed.
Study NCT05900362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalCare Platform
Description: All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
Study NCT05146180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parametric positron emission computed tomography
Description: Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
Study NCT04824339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group
Description: This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
Study NCT04824339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention Group
Description: This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
Study NCT06464601 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: fruquintinib combined with immune checkpoint inhibitors and chemotherapy
Description: Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles.
Study NCT05713656 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy care
Description: Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
Study NCT05613140 — intervention group
Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
Study NCT04928430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAV-19
Description: 150 mg of XAV-19 single IV perfusion
Study NCT04928430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion
Study NCT06406842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation index guided hemodynamics management
Description: In the autoregulation group, anesthesiologist will maintain that the cerebral oxygen index value below 0.3. If cerebral oxygen index exceeds the threshold, norepinephrine or phenylephrine will be infused continuously, or arterial partial pressure of oxygen or arterial partial pressure of carbon dioxide will be adjusted to increase regional cerebral oxygen saturation.
Study NCT05480410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
Study NCT04837898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Haskapa
Description: Haskapa Ltd, Oxford, UK
Study NCT04837898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isocaloric to the haskap powder
Study NCT05015907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The nerve involved in the operation of Hickman catheter, chemoport, and Perm cath is the supraclavicular nerve. Therefore, it is judged that if only this nerve is selectively blocked, pain control can be effectively performed with a small amount of local anesthetic, and relatively few side effects occur.
Study NCT05015907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (without intervention)
Description: No intervention
Study NCT04383808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injected radiotracer with PET Insert
Description: 1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.
Study NCT04383808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-injected group with PET insert
Description: 1. Informed consent will be obtained before beginning any study procedures.~2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.
Study NCT05060978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watch your Weight During the Holidays Program
Description: Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.
Study NCT05060978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relative 5:2 Fasting
Description: Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.
Study NCT05060978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
Study NCT06016673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
Study NCT06016673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
Study NCT06472193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shanfield implantation technique in Mitroffanof procedure
Description: a stab incision of the bladder wall 1-2 cm above the trigone is deepened down to the mucosa without penetrating it. The prolapsed mucosa is grasped through this window and incised. The spatulated appendix-Mitrofanoff is advanced through the window to the interior of the bladder and its lower lip is anchored to the trigone 1-2 cm distal to the stab wound with an appropriate size (4/0-6/0) vicryle suture using a U-stich. The stitch passes initially through the bladder wall to its interior, looping full thickness through posterior lip of the appendix, then back through the full thickness of the bladder wall to be knotted outside. Supplementary stitches are added externally between the adventitia of the conduit and the detrusor to stabilise the tube-bladder intersection. The detrusorotomy is closed over loosely forming a short subdetrusor tunnel. This technique will be done by open lower midline incision or by laparoscopy using 3 or 4-port access.
Study NCT04562870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
Study NCT04562870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice Treatment
Description: Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
Study NCT06583980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact
Description: A coordinating rheumatology nurse who follows the participant for six months, goal setting and action planning with the nurse, opportunity for needs based support from a physiotherapist, an occupational therapist and a social worker, opportunity for interdisciplinary conferences to coordinate support to achieve the agreed upon goals and a final status consultation.
Study NCT06584006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
Description: Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
Study NCT06584006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interleukin-2 Injections
Description: Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
Study NCT04774393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT04774393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study NCT04774393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study NCT04774393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06188637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod Oral Capsule
Description: open label ozanimod
Study NCT05430178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral sugar tolerance test
Description: Measurement of glucose and insulin for calculation of insulin sensitivity
Study NCT05430178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De novo lipogenesis test
Description: Oral consumption of deuterated water to measure incorporation of label into lipids
Study NCT05430178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluconeogenesis test
Description: Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
Study NCT06234761 — intervention group
Intervention type: DRUG
Intervention: Dupilumab
Description: Patient who start to take dupilumab will be followed. This study is only observational
Study NCT05045586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
Description: The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
Study NCT05045586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
Description: The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
Study NCT06452563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketoanalogue supplementation
Description: This drug contains 5 essential amino acids (L-lysine monoacetate 75mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg and L-tyrosine 30mg) and 5 essential amino acid substitutes in the form of calcium salts, including 4 keto-analogues (keto-isoleucine, keto-leucine, keto-valine, and keto-phenylalanine) and a hydroxy-analogue (hydro methionine) as calcium salt . The drug is approved by the Egyptian Drug Authority (EDA) with registration number 34677/2021
Study NCT06452563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intradialytic exercise
Description: low-intensity exercise training composed of knee extension and hip abduction and flexion from a three-repetition maximum (3RM) using ankle weights
Study NCT05721456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 12-Valent Pneumococcal Conjugate Vaccine
Description: PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
Study NCT05721456 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-Valent Pneumococcal Conjugate Vaccine
Description: PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
Study NCT05626621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray
Description: Participants will follow this medication regimen for 6 months.
Study NCT05626621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Nasal Irrigation (1 mg capsule)
Description: Participants will follow this medication regimen for 6 months.
Study NCT05626621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
Description: Participants will follow this medication regimen for 6 months.
Study NCT06284265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raphamin
Description: Tablet for oral use.
Study NCT06284265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study NCT05196152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MomMoodBooster
Description: MomMoodBooster is an empirically validated online intervention for perinatal women.
Study NCT05196152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MomMoodBooster
Description: MomMoodBooster is an empirically validated online intervention for perinatal women.
Study NCT05196152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Coaching
Description: Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
Study NCT05689372 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
Study NCT06012916 — intervention group
Intervention type: DRUG
Intervention: Esketamine nasal spray
Description: This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
Study NCT06057766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity tele coaching program
Description: The program includes~1. one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan;~2. step counter (Fitbit) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention;~3. smartphone coaching application (mPAC), installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.~4. phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).~Evidence-based behaviour change techniques will be implemented.
Study NCT04760782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
Study NCT04760782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hard collar immobilization
Description: Hard collar immobilization of the cervical spine for 12 weeks
Study NCT04760782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hard collar immobilization
Description: Hard collar immobilization of the cervical spine for 12 weeks